$WELNF
Integrated Wellness Acquisition Corp

2024 Q3 Form 10-Q Financial Statement

#000141057824001988 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $544.5K
YoY Change 71.17%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $558.2K
YoY Change 35.47%
Operating Profit -$558.2K
YoY Change 35.47%
Interest Expense $533.7K
YoY Change -29.41%
% of Operating Profit
Other Income/Expense, Net $533.7K
YoY Change -29.41%
Pretax Income -$24.47K
YoY Change -107.11%
Income Tax
% Of Pretax Income
Net Earnings -$24.47K
YoY Change -107.11%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.330K
YoY Change -55.77%
Cash & Equivalents $5.329K
Short-Term Investments
Other Short-Term Assets $41.25K
YoY Change 73.68%
Inventory
Prepaid Expenses $41.25K
Receivables
Other Receivables $1.153K
Total Short-Term Assets $47.73K
YoY Change 33.34%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $50.30M
YoY Change -14.83%
Other Assets
YoY Change
Total Long-Term Assets $50.30M
YoY Change -14.83%
TOTAL ASSETS
Total Short-Term Assets $47.73K
Total Long-Term Assets $50.30M
Total Assets $50.35M
YoY Change -14.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $405.0K
YoY Change 52.27%
Accrued Expenses $1.871M
YoY Change 47.66%
Deferred Revenue
YoY Change
Short-Term Debt $4.280M
YoY Change 139.08%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.789M
YoY Change 91.68%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $4.025M
YoY Change 0.0%
Total Long-Term Liabilities $4.025M
YoY Change 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.789M
Total Long-Term Liabilities $4.025M
Total Liabilities $10.81M
YoY Change 42.91%
SHAREHOLDERS EQUITY
Retained Earnings -$10.77M
YoY Change 42.96%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$10.77M
YoY Change
Total Liabilities & Shareholders Equity $50.35M
YoY Change -14.8%

Cashflow Statement

Concept 2024 Q3
OPERATING ACTIVITIES
Net Income -$24.47K
YoY Change -107.11%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities $240.4K
YoY Change -69.9%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 668.1K
YoY Change 39.19%
NET CHANGE
Cash From Operating Activities 240.4K
Cash From Investing Activities 0.000
Cash From Financing Activities 668.1K
Net Change In Cash 908.5K
YoY Change 108059.52%
FREE CASH FLOW
Cash From Operating Activities $240.4K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001877557
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Other Receivable After Allowance For Credit Loss Current Related Party Type Extensible Enumeration
OtherReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration
http://int.com/20240930#SponsorMember
CY2023Q4 us-gaap Other Receivable After Allowance For Credit Loss Current Related Party Type Extensible Enumeration
OtherReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration
http://int.com/20240930#SponsorMember
CY2024Q3 us-gaap Other Receivable After Allowance For Credit Loss Current Related Party Type Extensible Enumeration
OtherReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration
http://int.com/20240930#SponsorMember
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41131
dei Entity Registrant Name
EntityRegistrantName
INTEGRATED WELLNESS ACQUISITION CORP
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1615488
dei Entity Address Address Line1
EntityAddressAddressLine1
59 N. Main Street, Suite 1
dei Entity Address City Or Town
EntityAddressCityOrTown
Florida
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10921
dei City Area Code
CityAreaCode
845
dei Local Phone Number
LocalPhoneNumber
651-5039
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
true
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5329
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7567
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
41250
CY2024Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1153
CY2024Q3 us-gaap Assets Current
AssetsCurrent
47732
CY2023Q4 us-gaap Assets Current
AssetsCurrent
7567
CY2024Q3 wel Cash Held In Trust Noncurrent
CashHeldInTrustNoncurrent
50297550
CY2023Q4 wel Cash Held In Trust Noncurrent
CashHeldInTrustNoncurrent
47466611
CY2024Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
50297550
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
47466611
CY2024Q3 us-gaap Assets
Assets
50345282
CY2023Q4 us-gaap Assets
Assets
47474178
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1871171
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1179943
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
404968
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
348345
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6788991
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4107907
CY2024Q3 wel Deferred Underwriter Fee
DeferredUnderwriterFee
4025000
CY2023Q4 wel Deferred Underwriter Fee
DeferredUnderwriterFee
4025000
CY2024Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4025000
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4025000
CY2024Q3 us-gaap Liabilities
Liabilities
10813991
CY2023Q4 us-gaap Liabilities
Liabilities
8132907
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10766547
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8125628
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-10766259
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-8125340
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50345282
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
47474178
CY2024Q3 wel Formation And Operating Costs
FormationAndOperatingCosts
13746
CY2023Q3 wel Formation And Operating Costs
FormationAndOperatingCosts
93992
wel Formation And Operating Costs
FormationAndOperatingCosts
87715
wel Formation And Operating Costs
FormationAndOperatingCosts
338141
CY2024Q3 wel Accounting And Legal Expenses
AccountingAndLegalExpenses
443204
CY2023Q3 wel Accounting And Legal Expenses
AccountingAndLegalExpenses
201383
wel Accounting And Legal Expenses
AccountingAndLegalExpenses
1127079
wel Accounting And Legal Expenses
AccountingAndLegalExpenses
1338932
CY2024Q3 wel Listing Fee
ListingFee
21250
CY2023Q3 wel Listing Fee
ListingFee
21250
wel Listing Fee
ListingFee
63750
wel Listing Fee
ListingFee
63750
CY2024Q3 wel Insurance Expense
InsuranceExpense
50000
CY2023Q3 wel Insurance Expense
InsuranceExpense
88555
wel Insurance Expense
InsuranceExpense
93850
wel Insurance Expense
InsuranceExpense
320545
CY2023Q3 wel Advertising And Marketing Expense
AdvertisingAndMarketingExpense
6668
wel Advertising And Marketing Expense
AdvertisingAndMarketingExpense
18369
wel Advertising And Marketing Expense
AdvertisingAndMarketingExpense
161656
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
558200
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
412058
us-gaap Operating Expenses
OperatingExpenses
1720919
us-gaap Operating Expenses
OperatingExpenses
2223546
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-558200
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-412058
us-gaap Operating Income Loss
OperatingIncomeLoss
-1720919
us-gaap Operating Income Loss
OperatingIncomeLoss
-2223546
CY2024Q3 wel Interest Earned On Cash Held In Trust Account
InterestEarnedOnCashHeldInTrustAccount
533728
wel Interest Earned On Cash Held In Trust Account
InterestEarnedOnCashHeldInTrustAccount
1580939
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
797857
us-gaap Investment Income Interest
InvestmentIncomeInterest
3002579
CY2023Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-41724
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
251339
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
533728
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
756133
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1580939
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3253918
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-24472
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
344075
us-gaap Net Income Loss
NetIncomeLoss
-139980
us-gaap Net Income Loss
NetIncomeLoss
1030372
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-8125340
CY2024Q1 wel Adjustments To Additional Paid In Capital Sponsor Waiver Of Administrative Services Fee
AdjustmentsToAdditionalPaidInCapitalSponsorWaiverOfAdministrativeServicesFee
270000
CY2024Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1023484
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-37130
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-8915954
CY2024Q2 wel Adjustments To Additional Paid In Capital Sponsor Waiver Of Administrative Services Fee
AdjustmentsToAdditionalPaidInCapitalSponsorWaiverOfAdministrativeServicesFee
30000
CY2024Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
898727
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-78378
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-9863059
CY2024Q3 wel Adjustments To Additional Paid In Capital Sponsor Waiver Of Administrative Services Fee
AdjustmentsToAdditionalPaidInCapitalSponsorWaiverOfAdministrativeServicesFee
30000
CY2024Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
908728
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-24472
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-10766259
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3517421
CY2023Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
2415762
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
173235
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-5759948
CY2023Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1392022
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
513062
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-6638908
CY2023Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1236133
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
344075
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-7530966
us-gaap Profit Loss
ProfitLoss
-139980
us-gaap Profit Loss
ProfitLoss
1030372
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
251339
wel Sponsor Waiver Of Administrative Service Fee
SponsorWaiverOfAdministrativeServiceFee
-330000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
41250
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-341795
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
747851
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1263758
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
1153
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
193068
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
895468
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2577654
wel Payments Of Marketable Securities In Trust Account
PaymentsOfMarketableSecuritiesInTrustAccount
1790000
wel Proceeds From Reinvestment Of Dividends Received From Interest On Trust Account
ProceedsFromReinvestmentOfDividendsReceivedFromInterestOnTrustAccount
-3002579
wel Proceeds From Redemption Of Cash And Marketable Securities Held In Trust Account
ProceedsFromRedemptionOfCashAndMarketableSecuritiesHeldInTrustAccount
64980943
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
60188364
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1790000
wel Payments Made By Suntone Under Promissory Note Suntone
PaymentsMadeBySuntoneUnderPromissoryNoteSuntone
956339
wel Payments Made By Suntone Under Due To Suntone
PaymentsMadeBySuntoneUnderDueToSuntone
-976894
wel Payments For Redemption Of Common Stock
PaymentsForRedemptionOfCommonStock
64980943
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1933233
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-63190943
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2828701
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-424925
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47474178
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
436972
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50302879
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12047
wel Accretion Of Class Ordinary Shares Subject To Redemption Value
AccretionOfClassOrdinarySharesSubjectToRedemptionValue
2830939
wel Accretion Of Class Ordinary Shares Subject To Redemption Value
AccretionOfClassOrdinarySharesSubjectToRedemptionValue
5043917
us-gaap Notes Issued1
NotesIssued1
1533284
CY2022Q4 us-gaap Assets Held In Trust
AssetsHeldInTrust
0
wel Condition For Future Business Combination Number Of Businesses Minimum
ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum
1
CY2021Q4 wel Underwriting Discount
UnderwritingDiscount
2300000
CY2021Q4 wel Deferred Underwriting Discount
DeferredUnderwritingDiscount
4025000
CY2021Q4 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
497078
CY2023Q4 wel Monthly Payments Deposit Into Trust Account By Sponsor
MonthlyPaymentsDepositIntoTrustAccountBySponsor
160000
wel Adjustments To Liability Contribution From Sponsor
AdjustmentsToLiabilityContributionFromSponsor
2489623
wel Threshold Minimum Aggregate Fair Market Value As Percentage Of Net Assets Held In Trust Account.
ThresholdMinimumAggregateFairMarketValueAsPercentageOfNetAssetsHeldInTrustAccount.
0.80
CY2024Q3 wel Minimum Net Tangible Assets Upon Consummations Of Business Combination
MinimumNetTangibleAssetsUponConsummationsOfBusinessCombination
5000001
wel Threshold Percentage Of Public Shares Subject To Redemption Without Company Prior Written Consent
ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanyPriorWrittenConsent
0.15
wel Percentage Of Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1
wel Threshold Period From The Closing Of The Public Offering To Consummate A Business Combination As Per Amended And Restated Memorandum And Articles Of Association
ThresholdPeriodFromTheClosingOfThePublicOfferingToConsummateABusinessCombinationAsPerAmendedAndRestatedMemorandumAndArticlesOfAssociation
P18M
wel Threshold Period From The Closing Of The Public Offering Extends The Period Of Time To Consummate A Business Combination
ThresholdPeriodFromTheClosingOfThePublicOfferingExtendsThePeriodOfTimeToConsummateABusinessCombination
P21M
CY2023Q1 wel Monthly Payments Into Trust Account For Public Shareholders In Connection With Charter Extension
MonthlyPaymentsIntoTrustAccountForPublicShareholdersInConnectionWithCharterExtension
1150000
CY2023Q1 wel Payment Into Trust Account For Public Shareholders In Connection With Charter Extension For Each Share
PaymentIntoTrustAccountForPublicShareholdersInConnectionWithCharterExtensionForEachShare
0.10
CY2023Q2 wel Aggregate Amount To Be Deposited By Sponsor For Extension
AggregateAmountToBeDepositedBySponsorForExtension
160000
CY2023Q2 wel Amount To Be Deposited Into Trust Account For Public Shareholders In Connection With Extension For Each Share
AmountToBeDepositedIntoTrustAccountForPublicShareholdersInConnectionWithExtensionForEachShare
0.03
CY2023 wel Aggregate Amount To Be Deposited By Sponsor For Extension
AggregateAmountToBeDepositedBySponsorForExtension
960000
CY2023Q4 wel Aggregate Amount To Be Deposited By Sponsor For Extension
AggregateAmountToBeDepositedBySponsorForExtension
125000
CY2023Q4 wel Amount To Be Deposited Into Trust Account For Public Shareholders In Connection With Extension For Each Share
AmountToBeDepositedIntoTrustAccountForPublicShareholdersInConnectionWithExtensionForEachShare
0.03
wel Aggregate Amount To Be Deposited By Sponsor For Extension
AggregateAmountToBeDepositedBySponsorForExtension
1250000
wel Maximum Net Interests To Pay Dissolution Expenses
MaximumNetInterestsToPayDissolutionExpenses
100000
CY2024Q3 wel Minimum Per Share Amount To Be Maintained In The Trust Account
MinimumPerShareAmountToBeMaintainedInTheTrustAccount
10.20
CY2024Q3 wel Minimum Per Share Amount To Be Maintained In The Trust Account
MinimumPerShareAmountToBeMaintainedInTheTrustAccount
10.20
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5329
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7567
CY2024Q3 wel Working Capital Deficit Surplus
WorkingCapitalDeficitSurplus
6741259
CY2023Q4 wel Working Capital Deficit Surplus
WorkingCapitalDeficitSurplus
4100340
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 8pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:22.3pt;margin:0pt 0pt 12pt 8pt;">The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:22.3pt;margin:0pt 0pt 12pt 7.95pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p>
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2024Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2024Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-24472
CY2024Q3 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
908728
CY2024Q3 us-gaap Temporary Equity Net Income
TemporaryEquityNetIncome
-933200
us-gaap Net Income Loss
NetIncomeLoss
-139980
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
2830939
us-gaap Temporary Equity Net Income
TemporaryEquityNetIncome
-2970919
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
344075
CY2023Q3 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
1236133
CY2023Q3 us-gaap Temporary Equity Net Income
TemporaryEquityNetIncome
-892058
us-gaap Net Income Loss
NetIncomeLoss
1030372
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
5043917
us-gaap Temporary Equity Net Income
TemporaryEquityNetIncome
-4013545
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 7.95pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:22.3pt;margin:0pt 0pt 12pt 7.95pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed Federally insured limits. Exposure to cash and cash equivalents credit risk is reduced by placing such deposits with major financial institutions and monitoring their credit ratings. At September 30, 2024 and December 31, 2023, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p>
CY2024Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1153
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
0
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
wel Conversion Of Stock Additional Shares Issuable Percentage
ConversionOfStockAdditionalSharesIssuablePercentage
1
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001410578-24-001988-index-headers.html Edgar Link pending
0001410578-24-001988-index.html Edgar Link pending
0001410578-24-001988.txt Edgar Link pending
0001410578-24-001988-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
wel-20240930.xsd Edgar Link pending
wel-20240930x10q.htm Edgar Link pending
wel-20240930xex31d1.htm Edgar Link pending
wel-20240930xex31d2.htm Edgar Link pending
wel-20240930xex32d1.htm Edgar Link pending
wel-20240930xex32d2.htm Edgar Link pending
wel-20240930_cal.xml Edgar Link unprocessable
wel-20240930_def.xml Edgar Link unprocessable
wel-20240930_lab.xml Edgar Link unprocessable
wel-20240930_pre.xml Edgar Link unprocessable
wel-20240930x10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable